Unique MSANTD4 Protein: Potential Drug & Biomarker Target (G84437)

Target Name: MSANTD4

NCBI ID: G84437

MSANTD4

Other Name(s): KIAA1826 | Myb/SANT-like DNA-binding domain-containing protein 4 | Myb/SANT-like DNA-binding domain containing 4 with coiled-coils | Myb/SANT DNA binding domain containing 4 with coiled-coils, transcript variant 1 | MSANTD4 variant 1 | Myb/SANT DNA binding domain containing 4 with coiled-coils | MSD4_HUMAN | myb/SANT-like DNA-binding domain-containing protein 4

Unique MSANTD4 Protein: Potential Drug & Biomarker Target

MSANTD4 (KiAA1826) is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the superfamily of transmembrane protein (SMP) and is characterized by a unique arrangement of transmembrane domains.

One of the most interesting aspects of MSANTD4 is its unique structure. The protein has a transmembrane region that is made up of four尾-helices, each of which is held together by a disulfide bond. This arrangement is unique among SMP proteins, and it is thought to be responsible for the protein's unique function.

MSANTD4 is also known for its role in several important cellular processes. For example, it is involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues. It is also involved in the regulation of the blood-brain barrier, which is the barrier that separates the brain from the rest of the body and is responsible for ensuring that only certain substances can enter the brain.

In addition to its role in cell adhesion and the blood-brain barrier, MSANTD4 is also thought to be involved in the regulation of several other cellular processes. For example, it is involved in the regulation of cell proliferation, which is the process by which cells grow and divide, and it is also involved in the regulation of cell death, which is the process by which cells are destroyed when they are no longer needed.

MSANTD4 is also of interest because it is a potential drug target. Several studies have suggested that MSANTD4 may be a useful target for the development of new treatments for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One reason why MSANTD4 may be a good drug target is that it is thought to be involved in the regulation of a wide range of cellular processes, which makes it a potential target for drugs that can modulate these processes. For example, studies have suggested that MSANTD4 may be a good target for drugs that can inhibit its function in cell adhesion, as this process is thought to be involved in the development of many diseases, including cancer.

In addition to its potential as a drug target, MSANTD4 is also of interest because it is a potential biomarker. Studies have suggested that MSANTD4 may be a useful biomarker for the diagnosis and prognosis of a variety of diseases, including cancer. This is because the expression of MSANTD4 has been shown to be associated with the development and progression of many diseases, including cancer.

Overall, MSANTD4 is a protein that is of interest due to its unique structure and its role in several important cellular processes. While more research is needed, it is thought to be a potential drug target and a potential biomarker for a variety of diseases.

Protein Name: Myb/SANT DNA Binding Domain Containing 4 With Coiled-coils

The "MSANTD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MSANTD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets